cd38

CD38 inhibitor 1 is a potent CD38 inhibitor that is effective against human CD38 (IC50 value is 7.3 nM) and mouse CD38 (IC50 value is 1.9 nM).

Isatuximab is a monoclonal antibody targeting the transmembrane receptor and extracellular enzyme CD38 in malignant cells of the hematological system, a highly expressed protein in multiple myeloma. It exhibits antitumor activity, antibody-dependent cytotoxicity, complement-dependent cytotoxicity, and antibody-dependent cytophagocytosis, directly inducing apoptosis without crosslinking. Isatuximab inhibits CD38 extracellular enzyme activity, affecting various cellular functions.

RBN013209 is a potent CD38 inhibitor. RBN013209 is useful in the treatment of cancer.

CD38 inhibitor 2 is a potent CD38 inhibitor (IC 50 = 0.01 ~ 0.1 μΜ).

MK-0159 is an orally available, highly potent CD38 inhibitor with myocardial injury protection for the study of cardiac ischemia and reperfusion injury.

Felzartamab(MOR-202) is a human-targeted monoclonal antibody to CD38 for the study of multiple myeloma and advanced antibody-mediated rejection of allogeneic kidney transplants.

Mezagitamab (TAK-079) is a fully humanized IgG1λ monoclonal antibody against CD38 with high affinity for CD38-expressing cells (including plasma mother cells, plasma cells, and natural killer cells), which depletes CD38-expressing tumor cells through antibody- and complement-dependent cytotoxicity Mezagitamab may be used in the study of recurrent/refractory multiple myeloma (RRMM), which is the most common form of cancer. multiple myeloma (RRMM) and primary thrombocytopenic purpura (ITP).

CD38 Inhibitor 3 (compound 1), with an IC50 of 11 nM, is a potent agent that enhances mitochondrial biogenesis, diminishes lactate levels, and augments both NAD+ content and Nrf2 expression. In a Pus1 -/- mouse model of mitochondrial myopathy, it also elevates muscle function and bolstering exercise capacity [1].

Luteolinidin chloride is a natural product. It is a potent CD38 inhibitor which can protect the heart against I/R injury with preservation of eNOS function and prevention of endothelial dysfunction in vivo.

Anti-Mouse CD38 Antibody (NIMR5) is an IgG2a, κ inhibitor antibody derived from rats, designed to target and inhibit mouse CD38.

Anti-Human-CD38 Antibody (Daratumumab hexabody) is an antibody. Its expression system is HEK293 cells, and the isotype control is IgG1, Kappa.

NCD38 is a selective LSD1 (lysine-specific demethylase 1) inhibitor that activates super-enhancers and myeloid cell development programmes, exhibiting anti-leukaemia activity.

UCD38B HCl is a cell-permeable intracellular uPA inhibitor that acts by killing proliferative and non-proliferative high-grade glioma cells by programmed necrosis.

NCD38 TFA serves as a selective inhibitor of LSD1 [1] [2].

6-Alkyne-F-araNAD is an irreversible CD38 inhibitor that aids in better visualization of intracellular CD38 localization when used alongside other fluorescent probes (such as SR101−F-araNMN).

Ara-F-NAD+, an arabino analogue of NAD + , is a potent, slow-binding CD38 NADase inhibitor, with a K i of 169 nM.

Ara-F-NAD+ sodium, an arabino analogue of NAD+, serves as a potent, reversible, and slow-binding inhibitor of the CD38 NADase [1] [2].

Modakafusp alfa (TAK-573) is a humanized anti-CD38 IgG4 monoclonal antibody fused with 2 attenuated IFNα2b molecules, being researched for potential use in treating multiple myeloma [1].

Erzotabart is an IgG1-kappa monoclonal antibody that targets human CD38 (also known as ADP-ribosyl cyclase 1 or cyclic ADP-ribose hydrolase 1) and displays pronounced antineoplastic activity. Erzotabart acts by modulating CD38-mediated signaling pathways involved in tumor cell metabolism, proliferation, and immune evasion, making it a significant investigational candidate in oncology research.

Lumrotatug is a human-derived IgG1κ monoclonal antibody designed to target CD38. The isotype control for Lumrotatug is HumanIgG1kappa, Isotype Control.

SAR442257 is a humanized IgG4-S228P (κ type) monoclonal antibody designed to target CD38 on the surface of multiple myeloma cells, while also co-stimulating CD3 and CD28 molecules on T cells.

Daratumumab is a human monoclonal antibody that targets CD38 a cell surface protein that is overexpressed on multiple myeloma MM) cells.

Noraramtide (BHV-1100) is an antibody recruiting molecule that specifically binds to the CD38 molecule to recruit natural killer (NK) cells. This interaction enhances the NK cells' ability to kill tumor cells through antibody-dependent cellular cytotoxicity (ADCC). This mechanism allows NK cells to more effectively recognize and eliminate tumor cells while preventing mutual NK cell destruction. Noraramtide is utilized in research on autologous cancer immunotherapy.

Kuromanin chloride (Chrysontemin chloride) is potent antioxidants and free radical scavengers, may act as modulators of gene regulation and signal transduction pathways.